Literature DB >> 35940883

Primary care practice and cancer suspicion during the first three COVID-19 lockdowns in the UK: a qualitative study.

Claire Friedemann Smith1, Brian D Nicholson1, Yasemin Hirst2, Susannah Fleming3, Clare R Bankhead3.   

Abstract

BACKGROUND: The COVID-19 pandemic has profoundly affected UK primary care, and as a result the route to cancer diagnosis for many patients. AIM: To explore how the pandemic affected primary care practice, in particular cancer suspicion, referral, and diagnosis, and how this experience evolved as the pandemic progressed. DESIGN AND
SETTING: Seventeen qualitative interviews were carried out remotely with primary care staff.
METHOD: Staff from practices in England that expressed an interest in trialling an electronic safety-netting tool were invited to participate. Remote, semi-structured interviews were conducted from September 2020 to March 2021. Data analysis followed a thematic analysis and mind-mapping approach.
RESULTS: The first lockdown was described as providing time to make adjustments to allow remote and minimal-contact consultations but caused concerns over undetected cancers. These concerns were realised in summer and autumn 2020 as the participants began to see higher rates of late-stage cancer presentation. During the second and third lockdowns patients seemed more willing to consult. This combined with usual winter pressures, demands of the vaccine programme, and surging levels of COVID-19 meant that the third lockdown was the most difficult. New ways of working were seen as positive when they streamlined services but also unsafe if they prevented GPs from accessing all relevant information and resulted in delayed cancer diagnoses.
CONCLUSION: The post-pandemic recovery of cancer care is dependent on the recovery of primary care. The COVID-19 pandemic has highlighted and exacerbated vulnerabilities in primary care but has also provided new ways of working that may help the recovery.
© The Authors.

Entities:  

Keywords:  COVID-19; cancer; early diagnosis; general practice; remote consulting

Year:  2022        PMID: 35940883      PMCID: PMC9377348          DOI: 10.3399/BJGP.2021.0719

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   6.302


  22 in total

1.  Qualitative Research: Data Collection, Analysis, and Management.

Authors:  Jane Sutton; Zubin Austin
Journal:  Can J Hosp Pharm       Date:  2015 May-Jun

2.  Covid-19: Early stage cancer diagnoses fell by third in first lockdown.

Authors:  Matthew Limb
Journal:  BMJ       Date:  2021-05-07

3.  Diagnostic uncertainty: dichotomies are not the answer.

Authors:  Bethany Shinkins; Rafael Perera
Journal:  Br J Gen Pract       Date:  2013-03       Impact factor: 5.386

4.  Quality improvements of safety-netting guidelines for cancer in UK primary care: insights from a qualitative interview study of GPs.

Authors:  Alice Tompson; Brian D Nicholson; Sue Ziebland; Julie Evans; Clare Bankhead
Journal:  Br J Gen Pract       Date:  2019-11-28       Impact factor: 5.386

5.  Intensity and frequency of extreme novel epidemics.

Authors:  Marco Marani; Gabriel G Katul; William K Pan; Anthony J Parolari
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-31       Impact factor: 11.205

6.  Cancer detection in primary care: insights from general practitioners.

Authors:  T Green; K Atkin; U Macleod
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

7.  Understanding the impact of professional motivation on the workforce crisis in medicine: a rapid review.

Authors:  Efioanwan Andah; Blessing Essang; Charlotte Friend; Sarah Greenley; Kathryn Harvey; Maria Spears; Joanne Reeve
Journal:  BJGP Open       Date:  2021-04-26

8.  Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines: analysis of data from the UK General Practice Research Database.

Authors:  R D Neal; N U Din; W Hamilton; O C Ukoumunne; B Carter; S Stapley; G Rubin
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.